千亿注射剂赛道洗牌：齐鲁领跑，13款新品获批，独家品种暴涨92%

Core Insights - The injection market, valued at 450 billion, is experiencing a decline in overall sales, but biological drugs are emerging strongly, leading to significant changes in the TOP50 rankings [2][22] - The market is undergoing a phase of adjustment, with a 9.76% year-on-year decrease in sales for the first three quarters of 2025 [2][22] - The rise of exclusive products and the introduction of 13 new products into the TOP50 list indicate a dynamic and competitive landscape [7][10][22] Market Overview - The total sales of injections in hospitals reached over 450 billion in the first three quarters of 2025, showing a 9.76% decline compared to the previous year [2] - The injection sales fluctuated between 669.17 billion and 755.73 billion from 2018 to 2023, with a notable drop to 648.2 billion in 2024, reflecting a 7.98% decrease [2] - The leading therapeutic areas include blood and hematopoietic system drugs (22.75%), anti-tumor and immune-modulating drugs (22.27%), and systemic anti-infective drugs (14.6%), collectively accounting for nearly 60% of the market [2] Competitive Landscape - The TOP10 injection products accounted for 17.2% of the overall market share, indicating moderate market concentration but intense competition [6] - Notably, human albumin and sodium chloride injection each exceeded 17 billion in sales, showcasing the substantial size and activity within the injection sector [6] - The TOP50 list saw over 30 product rankings change, with 17 products rising in rank, including a standout iodine contrast agent that surpassed 2.2 billion in sales [7][10] Product Innovations - Fourteen exclusive products made it to the TOP50, with notable entries from companies like Innovent Biologics and BeiGene, including a product that recorded a 92.26% year-on-year sales increase [10][22] - The introduction of 13 new products into the TOP50 signifies a fresh influx of competition and innovation in the market [10][22] Regulatory Environment - The consistency evaluation for injections has gained momentum, with 359 applications and nearly 200 companies involved, indicating a robust regulatory framework supporting market expansion [15][20] - The competitive landscape is characterized by a split between domestic and foreign companies, with domestic leaders like Qilu Pharmaceutical showing strong performance alongside foreign firms in high-end biological drugs [20][21] Future Outlook - Despite the current decline in sales, the dominance of biological drugs and the growth of exclusive products are seen as positive indicators for future market dynamics [22] - The focus on quality, supply stability, and innovation will be crucial for companies to achieve sustained growth during this adjustment period [22]